Supportive Care in Cancer

, Volume 4, Issue 5, pp 370–377

Acute and anticipatory emesis in breast cancer patients

  • A. Fernández-Marcos
  • M. Martín
  • A. Rodriguez-Lescure
  • A. Casado
  • J. A. López Martin
  • E. Diaz-Rubio
  • J. J. Sanchez
Original Article

DOI: 10.1007/BF01788844

Cite this article as:
Fernández-Marcos, A., Martín, M., Rodriguez-Lescure, A. et al. Support Care Cancer (1996) 4: 370. doi:10.1007/BF01788844

Abstract

A group of 90 breast cancer patients undergoing chemotherapy were assessed prospectively to estimate the prevalence of acute (post-treatment) and anticipatory emesis in the 1990s. For this purpose, two protocols of chemotherapy were analysed separately: cyclophosphamide/methotrexate/5-fluorouracil (CMF) and 5-fluorouracil/doxorubicin/cyclophosphamide (FAC). All patients were treated with antiemetic therapy, which included one corticoid plus ondansetron (in the FAC regimen), or one corticoid plus thiethylperazine (in the CMF regimen). For at least one cycle of chemotherapy 86.1% and 91.7% patients in the FAC protocol presented vomiting and nausea respectively; 11.1% had anticipatory vomiting and 30.6% had anticipatory nausea. In the CMF protocol, 79.6% had post-chemotherapy vomiting and 71.7% had post-chemotherapy nausea associated with at least one cycle. In this group, 7.4% had anticipatory vomiting and 16.6% had anticipatory nausea. A high proportion of patients suffered anticipatory anxiety in both groups (75% in FAC, 74.1% in CMF). The stimuli most frequently associated with the appearance of anticipatory emesis were olfactory stimuli and cognitive stimuli. In summary, as a result of the advances made in antiemetic control during the last decade, the severity of chemotherapy-induced emesis seems to have significantly decreased, but the prevalence of these symptoms along the course of the treatment still remains high.

Key words

Prevalence Anticipatory emesisAcute emesisChemotherapy Ondansetron

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • A. Fernández-Marcos
    • 1
  • M. Martín
    • 1
  • A. Rodriguez-Lescure
    • 1
  • A. Casado
    • 1
  • J. A. López Martin
    • 1
  • E. Diaz-Rubio
    • 1
  • J. J. Sanchez
    • 2
  1. 1.Servicio de Oncología MédicaHospital Universitario San CarlosMadridSpain
  2. 2.Departamento de Bioestadística, Facultad de MedicinaUniversidad AutónomaMadridSpain